Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Санкт-Петербургский государственный университет, Санкт-Петербург, Россия 2 ЗАО «Фармфирма Сотекс», Россия 3 ФГБОУ ВО РНИМУ им. Н.И. Пирогова, Москва, Россия
Список исп. литературыСкрыть список 1. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. https://doi.org/10.1001/ jama.2020.1585. 2. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus. 2020;12(3):7352. Published 2020 Mar 21. doi:10.7759/cureus.7352 3. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832. doi:10.1016/j.jns.2020.116832 4. Ko CH, Yen CF, Yen JY, Yang MJ. Psychosocial impact among the public of the severe acute respiratory syndrome epidemic in Taiwan. Psychiatry Clin. Neurosci. 2006;60:397–403. 5. Mazza MG, De Lorenzo R, Conte C, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594-600. doi:10.1016/j.bbi.2020.07.037 6. Cheng SK, Tsang JS, Ku KH, Wong CW, Ng YK. Psychiatric complications in patients with severe acute respiratory syndrome (SARS) during the acute treatment phase: a series of 10 cases. Br J Psychiatry. 2004;184:359-60. doi: 10.1192/bjp.184.4.359. 7. Mak IW, Chu CM, Pan PC, Yiu MG, Chan VL. Long-term psychiatric morbidities among SARS survivors. Gen Hosp Psychiatry. 2009;31(4):318-326. doi:10.1016/j.genhosppsych.2009.03.001 8. Sønderskov KM, Dinesen PT, Santini ZI, Østergaard SD. The depressive state of Denmark during the COVID-19 pandemic. Acta Neuropsychiatr. 2020;32(4):226-228. doi:10.1017/neu.2020.15 9. Li S, Wang Y, Xue J, Zhao N, Zhu T. The Impact of COVID-19 Epidemic Declaration on Psychological Consequences: A Study on Active Weibo Users. Int J Environ Res Public Health. 2020;17(6):2032. Published 2020 Mar 19. doi:10.3390/ijerph17062032 10. Fernández-Aranda F, Casas M, Claes L, et al. COVID-19 and implications for eating disorders. Eur Eat Disord Rev. 2020;28(3):239-245. doi:10.1002/erv.2738 11. Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100-106. doi:10.1016/j.bbi.2020.04.069 12. Zhou J, Liu L, Xue P, Yang X, Tang X. Mental Health Response to the COVID-19 Outbreak in China. Am J Psychiatry. 2020;177(7):574-575. doi: 10.1176/appi.ajp.2020.20030304 13. Yuan R, Xu QH, Xia CC, et al. Psychological status of parents of hospitalized children during the COVID-19 epidemic in China. Psychiatry Res. 2020;288:112953. doi:10.1016/j.psychres.2020.112953 14. Chen Y, Zhou H, Zhou Y, Zhou F. Prevalence of self-reported depression and anxiety among pediatric medical staff members during the COVID-19 outbreak in Guiyang, China. Psychiatry Res. 2020;288:113005. doi:10.1016/j.psychres.2020.113005 15. Wu W, Zhang Y, Wang P, et al. Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy. J Med Virol. 2020;92(10):1962-1970. doi:10.1002/jmv.25914 16. Xiao H, Zhang Y, Kong D, Li S, Yang N. The Effects of Social Support on Sleep Quality of Medical Staff Treating Patients with Coronavirus Disease 2019 (COVID-19) in January and February 2020 in China. Med Sci Monit. 2020;26:e923549 doi:10.12659/MSM.923549 17. Lin CY, Peng YC, Wu YH, Chang J, Chan CH, Yang DY. The psychological effect of severe acute respiratory syndrome on emergency department staff. Emerg Med J. 2007;24(1):12-17. doi:10.1136/emj.2006.035089 18. Lancee WJ, Maunder RG, Goldbloom D.. Prevalence of psychiatric disorders among Toronto hospital workers one to two years after the SARS outbreak. Psychiatr. Serv. 2008;59:91–95. 19. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34-39. doi:10.1016/j.bbi.2020.04.027 20. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18-22. doi:10.1016/j.bbi.2020.03.031 21. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. 22. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5 23. Benedetti F, Poletti S, Hoogenboezem TA, Locatelli C, de Wit H, Wijkhuijs AJM, Colombo C, Drexhage HA. Higher Baseline Proinflammatory Cytokines Mark Poor Antidepressant Response in Bipolar Disorder. J Clin Psychiatry. 2017;78(8):986-993. doi: 10.4088/JCP.16m11310. 24. Benedetti F, Aggio V, Pratesi ML, Greco G, Furlan R. Neuroinflammation in Bipolar Depression. Front Psychiatry. 2020;11:71. Published 2020 Feb 26. doi:10.3389/fpsyt.2020.00071 25. de Girolamo G, Cerveri G, Clerici M, Monzani E, Spinogatti F, Starace F, Tura G, Vita A. Mental Health in the Coronavirus Disease 2019 Emergency-The Italian Response. JAMA Psychiatry. 2020;77(9):974-976. doi: 10.1001/jamapsychiatry.2020.1276. 26. Li W, Yang Y, Liu ZH, et al. Progression of Mental Health Services during the COVID-19 Outbreak in China. Int J Biol Sci. 2020;16(10):1732-1738. Published 2020 Mar 15. doi:10.7150/ijbs.45120 27. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet (London, England). 2020 28. Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. Published 2020 Mar 6. doi:10.3390/ijerph17051729 29. Cao W, Fang Z, Hou G, et al. The psychological impact of the COVID-19 epidemic on college students in China. Psychiatry Res. 2020;287:112934. doi:10.1016/j.psychres.2020.112934 30. Li G, Miao J, Wang H, Xu S, Sun W, Fan Y, Zhang C, Zhu S, Zhu Z, Wang W. Psychological impact on women health workers involved in COVID-19 outbreak in Wuhan: a cross-sectional study. J Neurol Neurosurg Psychiatry. 2020;91(8):895-897. doi: 10.1136/jnnp-2020-323134. 31. Mazza C, Ricci E, Biondi S, et al. A Nationwide Survey of Psychological Distress among Italian People during the COVID-19 Pandemic: Immediate Psychological Responses and Associated Factors. Int J Environ Res Public Health. 2020;17(9):3165. Published 2020 May 2. doi:10.3390/ijerph17093165 32. Du J, Dong L, Wang T, et al. Psychological symptoms among frontline healthcare workers during COVID-19 outbreak in Wuhan. Gen Hosp Psychiatry. 2020;67:144-145. doi:10.1016/j.genhosppsych.2020.03.011 33. Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020;66(5):504-511. doi: 10.1177/0020764020927051. 34. Lai J, Ma S, Wang Y, et al. Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Netw Open. 2020;3(3):e203976. doi:10.1001/jamanetworkopen.2020.3976 35. Huang Y, Zhao N. Chinese mental health burden during the COVID-19 pandemic [retracted in: Asian J Psychiatr. 2020 Dec;54:102482]. Asian J Psychiatr. 2020;51:102052. doi:10.1016/j.ajp.2020.102052 36. Taquet M., Luciano S., Geddes J.R., Harrison P.J. Bi-directional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The lancet Psychiatry. 2020 Nov 9;S2215- 0366;(20):30462–4. 37. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020; 7: 611–27. 38. Halpin S.J., McIvor C., Whyatt G., et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 2021; 93:1013. 39. Hosey M.M., Needham D.M. Survivorship after COVID-19 ICU stay. Nature Rev Dis Primers. 2020;6:1–2. 40. Writing Committee for the COMEBAC Study Group, Morin L., Savale L., et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA 2021; 325:1525. 41. Zhang J., et al.. The differential psychological distress of populations affected by the COVID-19 pandemic. Brain, Behav. Immun.2020 https://doi.org/10. 1016/j.bbi.2020. 04.031 42. Ayoubkhani D., Khunti K., Nafilyan V., et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021; 372:n693. 43. Huang C, Huang L, Wan Y et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet Vol. 397No. 10270p220–232Published: January 8, 2021 DOI:https://doi.org/10.1016/ S0140-6736(20)32656-8 44. Badenoch J, et al Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. medRxiv 2021.04.30.21256413; doi: https://doi.org/10.1101/2021.04.30.21256413 45. Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records (2021) The Lancet Psychiatry, 8 (5) , pp. 416-427 46. Carl E., Witcraft S.M., Kauffman B.Y., et al. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cogn. Behav. Ther. 2020; 49:1. 47. Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complement Ther Clin Pract. 2020;39:101132. doi:10.1016/j.ctcp.2020.101132 48. Király O, Potenza M, Stein D, King D, Hodgins D, Saunders J, Demetrovics Z. (2020). Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance. Comprehensive Psychiatry, 152180. doi:10.1016/j.comppsych.2020.152180 49. Малин Д.И., Рывкин П.В. Безопасность применения психотропных средств при осложнениях COVID-19 // Современная терапия психических расстройств. – 2021. – No 1. – С. 15 – 22. – DOI: 10.21265/PSYPH. 2021.63.59.003 50. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline. Published: 18 December 2020 www.nice.org.uk/ guidance/ng188 51. I-RECOVER Management Protocol for Long Haul COVID-19 Syndrome (LHCS) Version 1 June 16 2021 https://covid19criticalcare.com/covid-19-protocols/i-recover-protocol/ 52. Lenze E. et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. A Randomized Clinical Trial. JAMA. 2020;12: E1-E9. 53. Seftel D., Boulware B. Prospective cohort of fluvoxamine for early treatment of COVID-19, Open Forum Infectious Diseases, 2021;, ofab050, https://doi.org/10.1093/ofid/ofab050 54. Петрова Н.Н., Морозов П.В., Маркин А.В., Беккер Р.А., Быков Ю.В. Пандемия COVID-19: актуальные вызовы времени, а также новейшие данные к вопросу рационального выбора психофармакотерапии у пациентов с SARS-CoV-2. Психиатрия и психофармакотерапия. 2020; 6: 8–24. 55. Федин А.И. Соколова Л.П. Психологические и психовегетативные особенности COVID-19: Возможности медикаментозного воздействия. Невроньюс № 5 (79) 2021 с.4-5 56. Котова О.В., Медведев В.Э., Акарачкова Е.С., Беляев А.А. Ковид-19 и стресс-связанные расстройства. Журнал неврологии и психиатрии им. С.С. Корса-кова 2021, №5, 2, с. 128–134. https://doi.org/10.17116/jnevro2021121052128 57. Морозов П.В. Внесет ли психофармакология вклад в терапию COVID-19? Психиатрия и психофармакотерапия. 2021; 2. 58-61 58. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. Front Pharmacol. 2021 Apr 20;12:652688. doi: 10.3389/fphar.2021.652688. PMID: 33959018; PMCID: PMC8094534. 59. https://www.covid19treatmentguidelines.nih.gov/immunomodulators/fluvoxamine/ 60. COVID-19 early treatment: real-time analysis of 779 studies https://c19 early.com/